US 7,517,861 B2
	Immunostimulatory nucleic acid molecules
Arthur M. Krieg, Wellesley, Mass. (US); and Joel N. Kline, Iowa City, Iowa (US)
Assigned to University of Iowa Research Foundation, Iowa City, Iowa (US)
Filed on Jul. 09, 2004, as Appl. No. 10/888,785.
Application 09/818918 is a division of application No. 08/738652, filed on Oct. 30, 1996, granted, now 6,207,646.
Application 10/888785 is a continuation of application No. 09/818918, filed on Mar. 27, 2001, abandoned.
Application 08/738652 is a continuation in part of application No. 08/386063, filed on Feb. 07, 1995, granted, now 6,194,388.
Application 08/386063 is a continuation in part of application No. 08/276358, filed on Jul. 15, 1994, abandoned.
Prior Publication US 2005/0032736 A1, Feb. 10, 2005
Int. Cl. A61K 39/00 (2006.01); A61K 39/38 (2006.01); A61K 45/00 (2006.01); A61K 47/00 (2006.01); A61K 9/127 (2006.01); A61K 9/52 (2006.01); A61K 9/16 (2006.01); A61K 9/50 (2006.01); A61K 31/70 (2006.01); A01N 25/08 (2006.01); A01N 43/04 (2006.01); A61F 13/00 (2006.01)

U.S. Cl. 514—44  [424/184.1; 424/282.1; 424/278.1; 424/409; 424/434; 424/450; 424/457; 424/490]

12 Claims

1. A method of decreasing IgE in a subject who has been exposed to an allergen comprising administering to the subject an immunostimulatory oligonucleotide/delivery complex, said delivery complex comprising an oligonucleotide linked to a biodegradable delivery complex, wherein the oligonucleotide comprises the sequence 5′-C, G-3′, wherein the immunostimulatory oligonucleotide is 8 to 40 nucleotides in length and comprises: 5′ X1X2CGX3X43′, wherein C and G are unmethylated and X1, X2, X3, and X4 are nucleotides, in an amount sufficient to decrease IgE in the subject, wherein the decrease in IgE is relative to that observed in the subject who has been exposed to an allergen but is not treated with an immunostimulatory oligonucleotide/delivery complex.